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ABSTRACT 
 
We report the case of an 80-year-old female suffering from pancreatic cancer who 
developed severe non-alcoholic steatohepatitis (NASH) resulting in fatal hepatic 
failure after anti-cancer chemotherapy with gemcitabine. Hepatic encephalopathy 
appeared one year after the chemotherapy and the patient developed progressive liver 
failure and eventually died. Radiological examination showed severe fatty liver. 
Histopathological examination of a liver needle necropsy showed almost panlobular 
macrovesicular fatty change. Ballooning degeneration and necrosis of hepatocytes 
accompanying neutrophil infiltration, Mallory bodies, and a few bile plugs were 
found in zone 3. Marked perivenular and pericellular/perisinusoidal fibrosis and 
extensive bridging fibrosis were also found. Together, these findings indicated 
steatohepatitis at a precirrhotic stage. Because the patient had no history of drinking in 
excess, we made a diagnosis of NASH, in particular, chemotherapy-associated 
steatohepatitis (CASH). Gemcitabine is a pyrimidine nucleoside antimetabolite with 
anti-cancer activity. A few reports have mentioned fatal hepatotoxicity caused by 
gemcitabine but, to our knowledge, this is the first report of steatohepatitis, possibly 
associated with gemcitabine. Physicians treating patients with this drug should be 
aware of the possibility of steatohepatitis. 
 
Key words: gemcitabine, chemotherapy-associated steatohepatitis, non-alcoholic 
steatohepatitis, liver failure 
 
                                    Ren et al.  - 3 - 
INTRODUCTION 
 
Steatohepatitis can be categorized as alcoholic steatohepatitis (ASH) or 
non-alcoholic steatohepatitis (NASH), based on its etiopathogenesis.1 Ludwig 
primarily introduced NASH to describe a form of liver disease that is histologically 
indistinguishable from ASH, but occurs in patients that do not consume excess 
alcohol.2 Recently, NASH has been recognized as a hepatic manifestation of 
metabolic syndrome, associated with obesity, diabetic mellitus, and hyperlipidemia. 
This type of NASH is known as primary NASH.1 In contrast, secondary NASH is 
caused by jejunoileal bypass surgery, total parenteral nutrition, drugs, and industrial 
toxins. As for drug-induced steatohepatitis, consistent with the term ‘NASH’, the term 
"chemotherapy associated steatohepatitis" (CASH) has been proposed. Cases of 
drug-induced liver damage as well as the kinds of causative drugs have been 
increasing recently, but drug-induced liver injury showing the clinicopathological 
features of steatohepatitis is very rare.2 This is because in complex medical conditions, 
the diagnosis may be confounding, and the potential hepatotoxicity of 
chemotherapeutic agents may be easily overlooked.  
In this report, a fatal case of CASH which was possibly associated with 






The patient was an 80-year-old Japanese female. She had a history of hysterectomy 
for hysteromyoma, cholecystectomy for cholecystolithiasis, Basedow’s disease, and 
autonomic dystonia and had regularly gone to the hospital to treat autonomic dystonia. 
She was not a drinker. CT scan imaging revealed the presence of mass formation 
suggesting pancreatic cancer in the pancreatic head and the absence of definite fatty 
liver (Fig.1A) and the patient was admitted to initial hospital for the treatment in July 
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2004. Laboratory data at admission were follows; AST 29 [normal range, 12-36 IU/L], 
ALT 18 [3-32 IU/L], γGTP 17 [9-71 IU]), ALP 351 [114-394 IU/L], Amylase 166 
[58-166 IU/L], Pancreatic type 68 % [28-72%], Blood glucose level 111 [70-110 
mg/dl], Total cholesterol 176 [130-230], Triglyceride 81 [70-180 mg/dl], Platelet 17 
[15-35 x104], IgG 1180.0 [917-1850 mg/dl], IgM 86.7 [80-272 mg/dl], Viral markers 
for hepatitis (-), ANA <x40, CA19-9 54 [<37]. Obesity (68.3kg, BMI 29) and mild 
impaired glucose tolerance was found, but she had no prior medical history of hepatic 
disease and no sign of impaired liver function at this time. After admission, the peak 
weight was 70kg (BMI 29.9). Because the patient refused an operation, anti-cancer 
chemotherapy with gemcitabine (Gemzar®) in addition to camostat mesilate 
(Foipan®), Domperidone (Nauzelin®), loxoprofen sodium hydrate (Loxonin®), and 
tiquizium bromide (Thiaton®), had started at September 2004. Her symptoms 
partially improved during this anti-cancer treatment. However, because severe liver 
dysfunction and cognitive impairment, probably due to hepatic encephalopathy, 
appeared in October 2005 (13 months later after chemotherapy), chemotherapy was 
discontinued (Fig.2). Radiological findings concerning the pancreatic cancer did not 
changed, but severe fatty change was detected in the liver (Fig.1B). Then, she was 
admitted to next hospital for further examination of liver dysfunction, but she died of 
progressive hepatic failure 3 months after second admission. Liver function data just 
before death were follows; AST 78, ALT 46, total bilirubin 3.43, ALP 517, platelet 
17.1, prothrombin time 35%, and albumin 2.4 g/dl. A liver needle necropsy was 
performed.  
 
Histology of liver necropsy  
Histopathological examination of the liver revealed a pan-lobular fatty change, 
predominantly macrovesicular, involving approximately 90% of lobules (Fig.3). 
Ballooning degeneration and necrosis of hepatocytes accompanying neutrophil 
infiltration and bile plugs were found in zone 3 admixed with steatosis (Fig.4). These 
ballooned hepatocytes contained typical Mallory bodies consisting of dense and ropy 
hyaline (Fig.4). Portal tracts were fibrously expanded, and perivenular and 
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pericellular/perisinusoidal fibrosis in zone 3 was also prominent (Fig.5).  Extensive 
bridging fibrosis connecting central veins with other central veins and with portal 
tracts had developed, resulting in partial nodular remodeling and a pre-cirrhotic state 
(Fig.5). In portal tracts, mild infiltration of lymphocytes and neutrophils and mild 
interface hepatitis were found. We made a diagnosis of NASH (Grade 3, Stage 3),3 




Recently, cases of NASH are increasing and its etiology and mechanisms have 
been examined. Moreover, cases of drug-induced liver injury are also increasing and 
many drugs causing hepatic damage have been reported. Steatosis is one common 
pathological feature of drug-induced liver injury, but cases of steatohepatitis are very 
rare.2  
The liver histology of the patient described in this report was typical of 
steatohepatitis and alcohol history was not applicable in this case. Therefore, we made 
a diagnosis of NASH. In general, ASH and NASH are thought to have a similar 
histology.4 In fact, the two can be indistinguishable in terms of macrovesicular fatty 
change, fibers, and hepatocellular ballooning. However, detailed histological 
differences between ASH and NASH, particularly ASH and primary NASH, have 
been reported. For example, in cases of ASH, a typical Mallory body is found, but in 
cases of primary NASH, an atypical Mallory body that is ‘poorly formed’ and lacks 
the dense ropy quality of hyaline is seen.5 Moreover, neutrophil infiltration and 
hepatocellular necrosis are thought to be prominent in ASH, compared with NASH. 
Patients with ASH, therefore, generally show severe liver dysfunction. The 
histological features of secondary NASH including CASH depend on the etiology and 
drugs involved. 
Several drugs including nifedipine,6 tamoxifen,2 estrogen,2 corticosteroid,7 and 
methotrexate8 have been reported as causative of NASH. Among them, the 
anti-estrogen drug tamoxifen, is most well-known. Methotrexate, an antimetabolite, 
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has also been reported as a reagent causing NASH and liver fibrosis.8 In general, 
antimetabolites show hepatotoxicity. Gemcitabine (Gemzar®) is a novel analogue of 
deoxycytidine which inhibits DNA synthesis and acts as an antimetabolite with 
broad-spectrum anti-cancer activity including against pancreatic cancer.9 It is used as 
a standard medication for many cancers including pancreatic cancer and non-small 
cell lung cancer. Hepatotoxicity due to gemcitabine is known, but has repeatedly been 
described as a slight, transient, asymptomatic, and rapidly reversible elevation of AST 
and ALT levels.10,11 Therefore, gemcitabine does not have severe toxicity; however, 
fatal cases of liver injury involving veno-occlusive diseases12 and cholestatic liver 
failure13,14 that developed after treatment with gemcitabine have been reported.13,15 
This patient had obesity (BMI 29 at peak) and mild impaired glucose tolerance, 
but no fatty liver was found before the chemotherapy. Because the radiological 
findings of pancreatic cancer did not changed before and after the chemotherapy and 
no liver metastasis was not found, cancer-associated liver dysfunction causing the 
fatal course was unlikely in this case. Intrahepatic cholestasis as well as steatosis, 
moreover, was also found in the liver, suggesting the drug-associated liver injury. 
Therefore, the possibilities of other factors causing steatohepatitis are raised in this 
case, but the association of chemotherapy is likely in the pathogenesis of 
steatohepatitis. As mentioned above, two fatal cases of cholestatic liver failure related 
to gemcitabine therapy have been reported.13,14 The reason why this patient died of 
hepatic failure is unknown, but we speculated that the combined hepatocellular 
damage associated with steatohepatitis and cholestasis caused hepatic 
decompensation.  
The histological features of secondary NASH including CASH depend on the 
etiology and drugs involved. Several drugs including methotrexate, tamoxifen, and 
aminodarone, initially induce mitochondrial dysfunction through an impairment of 
beta-oxidation, which plays a central role in the pathogenesis of drug-induced 
steatosis and steatohepatitis and also in that of alcoholic cytotoxicity.2 Therefore, 
drug-induced steatohepatitis could show an ASH-like histology. This case also 
showed ASH-like histological features; typical Mallory bodies, prominent 
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neutrophilic infiltration and hepatocellular necrosis, and severe liver dysfunction 
resulting in lethal liver failure. These findings suggest that the cytotoxicity of 
gemcitabine is induced by a similar mechanism to that of ethanol. 
To our knowledge, this is the first case of possibly gemcitabine-induced 
steatohepatitis encountered during the treatment of pancreatic cancer. Recently, 
drug-induced hepatic damage has been broadly recognized, but as a special type of 
liver injury, physicians treating patients with this antitumor drug should be alert to the 
possibility of CASH. 
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